Numinus Wellness (TSXV: NUMI) this morning announced that it has entered into an arrangement with a subsidiary of the Multidisciplinary Association for Psychedelic Studies, also known as MAPS, to collaborate on a clinical trial that uses MDMA. The collaboration will see the duo collaborate for Health Canada approval to conduct an MDMA-assisted psychotherapy for PTSD through clinical trials.
Defined as being a single-arm, open-label, compassionate access trial, the purpose of the trial is to push towards increasing the accessibility of MDMA-based treatment options for those suffering from PTSD. The proposed program will see Numinus’ Vancouver clinic provide psychotherapy assisted by the use of MDMA to an initial group of twenty people that currently suffer from PTSD.
Data is to be collected on the outcome of the psychotherapy, along with safety data, which is to be provided to Health Canada. The trials are to be conducted under MAPS’ PTSD treatment protocol, with all staff, therapists and physicians to be trained under this protocol prior to approval by the regulatory agency.
Though this treatment is still investigational, if approval is granted through the regulatory pathway this collaboration will bolster our shared goal of addressing the enormous — and growing — need for improved proven treatments for people suffering from PTSD.
Amy Emerson, CEO of MAPS PBC
The clinical trial is to be the first of its kind in Canada. A timeline for the program has not yet been provided.
Sponsored · Antimony Resources
Numinus Wellness last traded at $0.68 on the TSX Venture.
Information for this briefing was found via Sedar and Numinus Wellness. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
